Edgewise Q3 net loss $17.5M ($0.34/shr); cash $365M; EDG-5506 shows biomarker reductions

Edgewise Therapeutics, Inc.

2022-Q3 EPS reported -$0.96

Cash, equivalents and marketable securities $365M as of Sept 30, 2022; underwritten offering raised $129M net.
Net loss $17.5M ($0.34 per share) vs $16.1M ($0.32) prior quarter; R&D spend $13.9M.
Positive 6-month ARCH interim data: CK reduced 39%, fast skeletal troponin I reduced 75% in BMD adults.
CANYON Phase 2 trial in BMD (n≈66) and LYNX Phase 2 trial in DMD (n≈27) both advancing; no approved treatments.
EDG-002 preclinical program targets hypertrophic cardiomyopathy; IND-enabling studies planned for 2022.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Edgewise Therapeutics, Inc. reported financial results for the third quarter ended September 30, 2022.

Period: the third quarter ended September 30, 2022
Result: reported results

Exact text from the filing

On November 3, 2022, Edgewise Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the third quarter ended September 30, 2022.

View on SEC.gov

Browse all earnings releases →

Edgewise Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001157523-22-001506

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.